Amylyx Pharmaceuticals Inc

AMLX remains in a strong uptrend across all horizons, but price is extremely overbought and extended above key EMAs after a parabolic gap rally. A multi-session consolidation just below $40 highlights indecision, and RSI in the low 80s warns of potential exhaustion. Lower-risk entry zones exist at the daily 9-EMA near $35 and the 20-EMA near $30. Execution is deferred (Stalk) until a clear pullback into these support areas or a decisive breakout above $40 on expanding volume.

• ↑Phase 3 LUCIDITY topline data expected Aug/Sep 2026; NDA ahead.
• ↑Cash of $250.8M funds R&D and operations through 2028 runway.
• ↓Q2 2026 net loss of $43.4M underscores unsustainable cash burn.